



Press Release 13 August 2025

Innovatrix agrees Partnership with TrialKey to revolutionise Clinical Trial Capital Management

London, United Kingdom – Innovatrix Capital Limited (“Innovatrix”) is pleased to announce the signing of a transformative agreement with TrialKey, the proprietary AI platform of Opyl Limited, a leading provider of AI-driven analytics for clinical trial risk assessment.

This strategic partnership will enable Innovatrix – a graduate of the Lloyd’s of London Lab accelerator programme - to advance further its pioneering parametric insurance solutions for clinical trial failure, leveraging TrialKey’s cutting-edge technology to deliver unparalleled risk transfer products for the global Life Sciences sector.

This collaboration represents a significant commercial and technological milestone for Innovatrix, reinforcing its position as a leader in innovative risk transfer for the global life sciences sector. Through this agreement, TrialKey will serve as the exclusive independent Calculation Agent for Innovatrix’s suite of parametric insurance products, providing mission-critical analytics that underpin our clinical trial capital management solutions.

TrialKey will provide comprehensive analytical services directly into Innovatrix’s proprietary CliniX rating engine. These robust analytics will form a core component of Innovatrix’s parametric solutions, enhancing its ability to serve clients with precision and confidence.

Innovatrix clients will also gain access to enhanced AI-driven analytics through TrialKey’s secure portal, creating new cross-selling opportunities and delivering enriched reporting. The partnership also includes joint marketing initiatives and strategic introductions to hedge funds, brokers, and pharmaceutical sponsors, expanding our reach and impact in the market.

“This partnership with TrialKey marks a pivotal moment in our mission to transform risk management for the life sciences sector,” said Innovatrix co-founders Piers Clark and Qasim Akbar. “By integrating TrialKey’s advanced AI-driven analytics into our parametric insurance solutions, we are empowering our clients with unprecedented precision and confidence in managing clinical trial outcome risk. Together, we are setting a new standard for innovation, transparency, and value in clinical trial capital management.”

-ends-

About Innovatrix Capital Limited

Innovatrix Capital Limited is a UK-based leader in innovative risk transfer and parametric insurance solutions, dedicated to supporting the global life sciences sector with cutting-edge products for clinical trial capital management. Through its proprietary **CliniX** parametric model, Innovatrix is developing data-driven insurance products that enable pharmaceutical and biotech companies to manage the financial risks of clinical trial outcomes.

About Opyl Limited

Opyl Limited (ASX: OPL) is an Australian technology company applying artificial intelligence to improve the efficiency, success, and transparency of clinical trials. Opyl's core platform, TrialKey, is an AI-powered decision-support tool that predicts the probability of success for clinical trials and helps sponsors optimise trial design and planning. The company is committed to transforming drug development by reducing risk, improving resource allocation, and unlocking data-driven innovation across the life sciences sector.

For all enquiries, please contact:

info@innovatrixcap.co.uk